Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06607848

Comparison of Two Non- Diffractive Extended Depth of Focus Intraocular Lenses

Intra-individual comparison of the PureSee EDOF IOL with the Acunex Vario EDOF IOL set for emmetropia.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year–105 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Spectacle-independence is a growing goal in modern cataract surgery. The procedure has evolved from a simple restoration of vision to a presbyopia correction approach. Although bilateral monofocal IOL implantation with the goal of emmetropia results in high patient satisfaction for distance vision, spectacle-dependence for reading and intermediate vision tasks is the usual outcome.

Enhanced Depth of Focus (EDOF) lenses have been on the market for some time to minimize this spectacle-dependency in intermediate tasks (computer work, dashboard, etc.). These IOLs have an extended distance focal range that extends into the intermediate distance, providing high quality vision over a continuous focal range, rather than single foci with blurring in between. The risk to the patient is comparable to that of all other monofocal systems, which generally have high patient satisfaction. The benefit of this study should be continuous sharp binocular vision at distance, intermediate (66 cm) and even near (40 cm). Another expected effect is the reduction of dysphotopic phenomena compared to other EDOF lenses.

The aim of this study is to compare the visual performance of two refractive EDOF lenses, namely the Acunex Vario with the Puresee IOL, in an intraindividual comparative study design. In order to achieve a satisfactory result, we planned to include 40 patients scheduled for cataract surgery in the study.

The examinations will all take place one week before, 1 week and 4-6 months after the operation. These include a visual acuity check at the three distances mentioned, slit lamp examination, pressure control, biometry, pupil width, defocus curve, quality of vision questionnaires, contrast sensitivity, halo&glare, optical coherence tomography, fundus examination, aberrometry and keratometry.

The main parameter to be examined is the distance-corrected visual acuity for the intermediate distance (66 cm) between the two IOLs at the follow-up examination after 4-6 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age-related bilateral cataract
  • Age 21 or older
  • Visual acuity > 0.05
  • For patients with regular corneal astigmatism greater than or equal to 1.00 dpt toric IOLs will be implanted
  • Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically relevant
  • Written informed consent prior to surgery

Exclusion criteria

  • Active ocular disease (e.g chronic uveitis, diabetic retinopathy, chronic glaucoma not responsive to medication, corneal dystrophies, etc.) precluding good post-operative visual acuity
  • Relevant other ophthalmic diseases such as pseudoexfoliation syndrome (PEX)
  • Corneal decompensation or corneal endothelial cell insufficiency
  • Irregular astigmatism on corneal tomography
  • Pronounced dry eye disease
  • Previous ocular surgery or trauma
  • Persons who are pregnant or nursing (pregnancy test will be taken in women of reproductive age)

Treatment and study plan

Low-Add EDOF IOL

Device

Acunex Vario AN6V

EDOF IOL

Device

PureSee EDOF IOL

Primary outcomes

  1. Distance corrected visual acuity for intermediate distance

    Time frame: 6 months

    Distance corrected visual acuity for intermediate distance given in logMAR will be measured at 66 cm using ETDRS charts

Secondary outcomes

  1. Uncorrected visual acuity for intermediate distance

    Time frame: 6 months

    Uncorrected visual acuity for intermediate distance given in logMAR will be measured at 66 cm using ETDRS charts

  2. Uncorrected and distance corrected visual acuity for far distance

    Time frame: 6 months

    Uncorrected and distance corrected visual acuity for far distance given in logMAR will be measured at 4 m using ETDRS charts

  3. Uncorrected and distance corrected visual acuity for near distance

    Time frame: 6 months

    Uncorrected and distance corrected visual acuity for near distance given in logMAR will be measured at 40 cm using ETDRS charts

  4. Defocus curve assessment

    Time frame: 6 months

    Monocular defocus curves will be assessed in logMAR at 4 m using an ETDRS chart

  5. Halometry

    Time frame: 6 months

    Potential halos will be assessed using the Aston Halometer App provided on a Tablet at 2 m

  6. Contrast sensitivity

    Time frame: 6 months

    Contrast sensitivity will be tested using the Optec device

  7. Subjective rating of dysphotopsia

    Time frame: 6 months

    Dysphotopsia will be subjectively rated by the patients using a questionnaire and a visual analogue scale

Study contacts

Contact information is provided by the study sponsor or research team.

Johannes Zeilinger, MD

CONTACT

[email protected]

01 91021 57564

Manuel Ruiss, MSc

CONTACT

[email protected]

01 91021 57564

Sponsors and collaborators

Lead sponsor

Vienna Institute for Research in Ocular Surgery

Other

Registry information

Official study title

Intraindividual Comparison of Two Non- Diffractive Extended Depth of Focus Intraocular Lenses Set for Emmetropia

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Sep 23, 2024
Registry last updated
Sep 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.